Agilent Technologies, Inc. and Picometrics Technologies have signed a co-marketing agreement to provide combined solutions for capillary electrophoresis (CE), laser induced fluorescence (LIF) detection, and mass spectrometry, to biopharmaceutical customers. The collection of tools will provide an online CE-LIF-MS solution suitable for R&D of complex large-molecule compounds.
“We are very pleased to extend a long-standing and fruitful partnership with Agilent and consolidate our development strategy,” said Jean Charles Garcia, president of Picometrics. “This unique technological platform using our new-generation LIF detection will significantly increase efficiency for biotherapeutic characterization in research, development and quality control.”
“We are excited to collaborate with Picometrics and provide this unique product offering to the biopharmaceutical industry—particularly those focusing on the research and development of NBEs, or new biological entities,” said Michael Frank, Agilent marketing director, liquid phase separations. “As conventional drug research becomes outmoded in meeting the increasing demands of complex, large-molecule drug development, scientists need highly sophisticated tools like these to advance therapeutic discovery.”
Agilent, Picometrics In Mass Spec Pact
By Kristin Brooks
Published January 17, 2014
blog comments powered by Disqus